Cargando…

Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma

Glioblastoma (GBM) is the most common malignant adult brain tumor that is resistant to the standard care therapy. Advances in chimeric antigen receptor (CAR) T cell therapies have spurred renewed interest in developing CAR T cell therapies to target chemoradiotherapy-resistant brain tumor-initiating...

Descripción completa

Detalles Bibliográficos
Autores principales: Tatari, Nazanin, Maich, William T., Salim, Sabra K., Mckenna, Dillon, Venugopal, Chitra, Singh, Sheila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757398/
https://www.ncbi.nlm.nih.gov/pubmed/33377068
http://dx.doi.org/10.1016/j.xpro.2020.100174
Descripción
Sumario:Glioblastoma (GBM) is the most common malignant adult brain tumor that is resistant to the standard care therapy. Advances in chimeric antigen receptor (CAR) T cell therapies have spurred renewed interest in developing CAR T cell therapies to target chemoradiotherapy-resistant brain tumor-initiating cells. This protocol shows how to isolate peripheral blood mononuclear cells from healthy donors and generate CAR T cells for the antigens of interest, and how to intracranially inject the CAR T cells into a patient-derived xenograft mouse model of GBM. For complete details on the use and execution of this protocol, please refer to Vora et al. (2020).